Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario.

Girona J, Rodríguez-Borjabad C, Ibarretxe D, Vallvé JC, Ferré R, Heras M, Rodríguez-Calvo R, Guaita-Esteruelas S, Martínez-Micaelo N, Plana N, Masana L.

J Clin Med. 2019 Oct 26;8(11). pii: E1793. doi: 10.3390/jcm8111793.

2.

HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk.

Girona J, Amigó N, Ibarretxe D, Plana N, Rodríguez-Borjabad C, Heras M, Ferré R, Gil M, Correig X, Masana L.

Int J Mol Sci. 2019 Jun 27;20(13). pii: E3151. doi: 10.3390/ijms20133151.

3.

Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.

Masana L, Ibarretxe D, Rodríguez-Borjabad C, Plana N, Valdivielso P, Pedro-Botet J, Civeira F, López-Miranda J, Guijarro C, Mostaza J, Pintó X; Expert group from the Spanish Arteriosclerosis Society.

Atherosclerosis. 2019 Aug;287:89-92. doi: 10.1016/j.atherosclerosis.2019.06.905. Epub 2019 Jun 20. Review.

PMID:
31238171
4.

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.

Ben-Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, Bogsrud MP, Araujo M, Hussein O, Ibarretxe D, Sanchez-Hernández RM, Santos RD.

Adv Ther. 2019 Jul;36(7):1786-1811. doi: 10.1007/s12325-019-00985-8. Epub 2019 May 17.

5.

Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.

Ibarretxe D, Rodríguez-Borjabad C, Feliu A, Bilbao JÁ, Masana L, Plana N.

Atherosclerosis. 2018 Nov;278:210-216. doi: 10.1016/j.atherosclerosis.2018.09.039. Epub 2018 Oct 1.

PMID:
30312929
6.

Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting.

Martín-Campos JM, Plana N, Figueras R, Ibarretxe D, Caixàs A, Esteve E, Pérez A, Bueno M, Mauri M, Roig R, Martínez S, Pintó X, Masana L, Julve J, Blanco-Vaca F; Xarxa d’Unitats de Lípids i Arteriosclerosi (XULA).

J Clin Lipidol. 2018 Nov - Dec;12(6):1452-1462. doi: 10.1016/j.jacl.2018.09.002. Epub 2018 Sep 7.

PMID:
30293936
7.

Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society.

Ariza MJ, Rioja J, Ibarretxe D, Camacho A, Díaz-Díaz JL, Mangas A, Carbayo-Herencia JA, Ruiz-Ocaña P, Lamíquiz-Moneo I, Mosquera D, Sáenz P, Masana L, Muñiz-Grijalvo O, Pérez-Calahorra S, Valdivielso P; Spanish Dyslipidemia Registry.

J Clin Lipidol. 2018 Nov - Dec;12(6):1482-1492.e3. doi: 10.1016/j.jacl.2018.07.013. Epub 2018 Aug 1.

PMID:
30150141
8.

Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti-β2 -Glycoprotein I and Small Dense High-Density Lipoprotein Particles.

Parra S, Lopez-Dupla M, Ibarretxe D, de Las Heras M, Amigó N, Català A, Benavent M, Garcés E, Navarro A, Castro A.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):116-125. doi: 10.1002/acr.23594.

9.

Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project.

Plana N, Rodríguez-Borjabad C, Ibarretxe D, Ferré R, Feliu A, Caselles A, Masana L; en representación del proyecto DECOPIN.

Clin Investig Arterioscler. 2018 Jul - Aug;30(4):170-178. doi: 10.1016/j.arteri.2017.12.003. Epub 2018 Mar 27. English, Spanish.

PMID:
29602595
10.

Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.

Rodríguez-Borjabad C, Ibarretxe D, Girona J, Ferré R, Feliu A, Amigó N, Guijarro E, Masana L, Plana N; DECOPIN Group.

Atherosclerosis. 2018 Mar;270:117-122. doi: 10.1016/j.atherosclerosis.2018.01.040. Epub 2018 Jan 31.

PMID:
29407879
11.

Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis.

Masana L, Girona J, Ibarretxe D, Rodríguez-Calvo R, Rosales R, Vallvé JC, Rodríguez-Borjabad C, Guardiola M, Rodríguez M, Guaita-Esteruelas S, Oliva I, Martínez-Micaelo N, Heras M, Ferré R, Ribalta J, Plana N.

J Clin Lipidol. 2018 Mar - Apr;12(2):292-299.e3. doi: 10.1016/j.jacl.2017.12.018. Epub 2018 Jan 8. Review.

PMID:
29398429
12.

Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.

Girona J, Rodríguez-Borjabad C, Ibarretxe D, Heras M, Amigo N, Feliu A, Masana L, Plana N; DECOPIN Group.

J Clin Lipidol. 2018 Jan - Feb;12(1):211-218. doi: 10.1016/j.jacl.2017.10.003. Epub 2017 Oct 12.

PMID:
29102496
13.

Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association.

Ibarretxe D, Pellejà J, Ortiz N, Masana L.

J Clin Lipidol. 2017 Sep - Oct;11(5):1280-1283. doi: 10.1016/j.jacl.2017.07.009. Epub 2017 Aug 1.

PMID:
28807458
14.

How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?

Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F; Dyslipidemia Registry of the Spanish Arteriosclerosis Society.

Atherosclerosis. 2017 Jul;262:107-112. doi: 10.1016/j.atherosclerosis.2017.05.013. Epub 2017 May 12.

PMID:
28531826
15.

Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease.

Rodríguez-Calvo R, Girona J, Alegret JM, Bosquet A, Ibarretxe D, Masana L.

J Endocrinol. 2017 Jun;233(3):R173-R184. doi: 10.1530/JOE-17-0031. Epub 2017 Apr 18. Review.

PMID:
28420707
16.

Familial hypercholesterolemia in childhood and adolescents: A hidden reality.

Plana N, Rodríguez-Borjabad C, Ibarretxe D, Masana L.

Clin Investig Arterioscler. 2017 May - Jun;29(3):129-140. doi: 10.1016/j.arteri.2016.11.002. Epub 2017 Apr 5. English, Spanish.

PMID:
28390853
17.

APOA5 genetic and epigenetic variability jointly regulate circulating triacylglycerol levels.

Oliva I, Guardiola M, Vallvé JC, Ibarretxe D, Plana N, Masana L, Monk D, Ribalta J.

Clin Sci (Lond). 2016 Nov 1;130(22):2053-2059. doi: 10.1042/CS20160433. Epub 2016 Sep 9.

PMID:
27613158
18.

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.

Girona J, Ibarretxe D, Plana N, Guaita-Esteruelas S, Amigo N, Heras M, Masana L.

Cardiovasc Diabetol. 2016 Aug 4;15(1):107. doi: 10.1186/s12933-016-0428-z.

19.

Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders.

Ibarretxe D, Girona J, Amigó N, Plana N, Ferré R, Guaita S, Mallol R, Heras M, Masana L.

J Clin Lipidol. 2016 Mar-Apr;10(2):330-8.e2. doi: 10.1016/j.jacl.2015.12.012. Epub 2015 Dec 22.

PMID:
27055964
20.

Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis.

Ariza MJ, Martínez-Hernández PL, Ibarretxe D, Rabacchi C, Rioja J, Grande-Aragón C, Plana N, Tarugi P, Olivecrona G, Calandra S, Valdivielso P.

J Clin Lipidol. 2016 Jan-Feb;10(1):92-100.e1. doi: 10.1016/j.jacl.2015.09.007. Epub 2015 Sep 25.

PMID:
26892125

Supplemental Content

Loading ...
Support Center